Nitric oxide releasing graphene for next-generation therapeutics
Advanced Drug Delivery Reviews · 2025-11 · 226 · 115676
DOI: 10.1016/j.addr.2025.115676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025-11. Verfasst von Tanveer A Tabish und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation (BHF) Centre of Research Excellence, University of Ox…. Hauptthemen laut MEDLINE: Nitric Oxide, Graphite, Drug Carriers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, British Heart Foundation (BHF).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation (BHF) Centre of Research Excellence, University of Oxford, Oxford OX3 7BN, United Kingdom. Electronic address: tanveer.tabi…
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation (BHF) Centre of Research Excellence, University of Oxford, Oxford OX3 7BN, United Kingdom; School of Cardiovascular and Met…
Förderung
- Wellcome Trust
- British Heart Foundation (BHF)
Zitieren
APA
Tabish, T. A., & Lygate, C. A. (2025). Nitric oxide releasing graphene for next-generation therapeutics. Advanced Drug Delivery Reviews, 226, 115676. https://doi.org/10.1016/j.addr.2025.115676
Vancouver
Tabish TA, Lygate CA. Nitric oxide releasing graphene for next-generation therapeutics. Advanced Drug Delivery Reviews. 2025;226:115676. doi:10.1016/j.addr.2025.115676
BibTeX
@article{Tabish2025,
author = {Tabish, Tanveer A and Lygate, Craig A},
title = {Nitric oxide releasing graphene for next-generation therapeutics},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
volume = {226},
pages = {115676},
doi = {10.1016/j.addr.2025.115676}
}
EUVIMED